Buckhead Capital Management’s GSK GSK Stock Holding History

Buckhead Capital Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,139	Closed	-$251K	–	127
2024 Q3	$251K	Sell	6,139 -4,238	-41%	-$173K	0.08%	113
2024 Q2	$400K	Sell	10,377 -103,157	-91%	-$4.34M	0.14%	88
2024 Q1	$4.87M	Buy	113,534 +6,481	+6%	+$267K	1.65%	24
2023 Q4	$3.97M	Buy	107,053 +762	+0.7%	+$27.4K	1.47%	28
2023 Q3	$3.85M	Sell	106,291 -82,202	-44%	-$2.92M	1.6%	23
2023 Q2	$6.72M	Sell	188,493 -8,419	-4%	-$302K	1.6%	19
2023 Q1	$7.01M	Buy	196,912 +2,905	+1%	+$102K	1.65%	17
2022 Q4	$6.82M	Sell	194,007 -41,271	-18%	-$1.37M	1.65%	23
2022 Q3	$6.92M	Buy	+235,278	New	+$8.92M	1.79%	19
2022 Q2	–	Sell	-33,455	Closed	-$1.82M	–	131
2022 Q1	$1.82M	Buy	33,455 +341	+1%	+$18.5K	0.39%	74
2021 Q4	$1.82M	Buy	33,114 +495	+2%	+$25.7K	0.39%	72
2021 Q3	$1.56M	Buy	32,619 +1,760	+6%	+$88.4K	0.35%	75
2021 Q2	$1.54M	Buy	30,859 +669	+2%	+$32.1K	0.34%	77
2021 Q1	$1.35M	Buy	30,190 +460	+2%	+$20.9K	0.31%	73
2020 Q4	$1.37M	Buy	29,730 +3,914	+15%	+$180K	0.34%	67
2020 Q3	$1.22M	Buy	25,816 +2,668	+12%	+$134K	0.35%	65
2020 Q2	$1.18M	Hold	23,148	–	–	0.36%	58
2020 Q1	$1.1M	Hold	23,148	–	–	0.41%	59
2019 Q4	$1.36M	Hold	23,148	–	–	0.38%	61
2019 Q3	$1.24M	Buy	23,148 +3,196	+16%	+$164K	0.35%	66
2019 Q2	$998K	Hold	19,952	–	–	0.3%	69
2019 Q1	$1.04M	Hold	19,952	–	–	0.32%	70
2018 Q4	$953K	Buy	19,952 +240	+1%	+$11.8K	0.33%	69
2018 Q3	$990K	Buy	19,712 +180	+0.9%	+$9.14K	0.3%	74
2018 Q2	$984K	Buy	19,532 +1,492	+8%	+$75.1K	0.32%	72
2018 Q1	$881K	Sell	18,040 -2,120	-11%	-$98.7K	0.19%	107
2017 Q4	$894K	Buy	20,160 +5,912	+41%	+$273K	0.19%	111
2017 Q3	$723K	Buy	14,248 +572	+4%	+$29K	0.16%	115
2017 Q2	$737K	Hold	13,676	–	–	0.13%	109
2017 Q1	$721K	Buy	13,676 +5,012	+58%	+$254K	0.13%	109
2016 Q4	$417K	Hold	8,664	–	–	0.08%	137
2016 Q3	$467K	Hold	8,664	–	–	0.09%	141
2016 Q2	$469K	Buy	8,664 +2,104	+32%	+$111K	0.09%	154
2016 Q1	$333K	Hold	6,560	–	–	0.06%	164
2015 Q4	$331K	Buy	+6,560	New	+$334K	0.06%	173
2015 Q3	–	Sell	-6,492	Closed	-$338K	–	197
2015 Q2	$338K	Buy	6,492 +548	+9%	+$30.9K	0.06%	178
2015 Q1	$343K	Hold	5,944	–	–	0.06%	171
2014 Q4	$318K	Hold	5,944	–	–	0.06%	176
2014 Q3	$342K	Hold	5,944	–	–	0.06%	179
2014 Q2	$397K	Buy	5,944 +856	+17%	+$57.9K	0.06%	183
2014 Q1	$340K	Hold	5,088	–	–	0.04%	183
2013 Q4	$340K	Sell	5,088 -124	-2%	-$8.04K	0.04%	179
2013 Q3	$327K	Buy	+5,212	New	+$336K	0.04%	172

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Buckhead Capital Management's GSK Position: Q4 2024 in Review

Buckhead Capital Management sold out of GSK (GSK) in Q4 2024, closing a stake of 6,139 shares — an estimated $251K sold.

Buckhead Capital Management first reported a position in GSK in Q3 2013 and held it in 43 quarters. The position peaked at $7.01M in Q1 2023. 849 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

Buckhead Capital Management reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
Buckhead Capital Management sold 6,139 GSK shares in Q4 2024, an estimated $251K.
Buckhead Capital Management first reported a position in GSK in Q3 2013 and held it in 43 quarters.
Buckhead Capital Management's GSK position peaked at $7.01M in Q1 2023.
849 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Buckhead Capital Management's 13F filing for Q4 2024, filed 30 Jan 2025.